List of Excipients in Branded Drug LASTACAFT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	LASTACAFT	alcaftadine	0023-4290	BENZALKONIUM CHLORIDE
Allergan Inc	LASTACAFT	alcaftadine	0023-4290	EDETATE DISODIUM
Allergan Inc	LASTACAFT	alcaftadine	0023-4290	HYDROCHLORIC ACID
Allergan Inc	LASTACAFT	alcaftadine	0023-4290	SODIUM CHLORIDE
Allergan Inc	LASTACAFT	alcaftadine	0023-4290	SODIUM HYDROXIDE
Allergan Inc	LASTACAFT	alcaftadine	0023-4290	SODIUM PHOSPHATE, MONOBASIC

Lastacaft Excipient Strategy and Commercial Opportunities for Alcaftadine Ophthalmic Solution

Last updated: August 2, 2026

Lastacaft is an alcaftadine 0.25% ophthalmic solution for allergic conjunctivitis. Its commercial position is based on once-daily dosing, over-the-counter availability, and a conventional aqueous formulation. The product’s excipient system is technically simple, which limits composition-of-matter differentiation but creates opportunities in preservative-free delivery, multidose packaging, ocular-surface tolerability, and lifecycle reformulation.

What is the Lastacaft formulation and which excipients does it contain?

Lastacaft contains alcaftadine at 0.25% in an aqueous ophthalmic solution. The labeled inactive ingredients are benzalkonium chloride, sodium phosphate monobasic, sodium phosphate dibasic, edetate disodium, hydrochloric acid and/or sodium hydroxide for pH adjustment, and purified water.[1]

Formulation element	Lastacaft role	Commercial relevance
Alcaftadine 0.25%	Active antihistamine and mast-cell stabilizing agent	Once-daily allergy treatment
Benzalkonium chloride 0.01%	Preservative	Enables multidose bottle use; creates ocular-surface tolerability concerns
Sodium phosphate monobasic and dibasic	Buffer system	Maintains formulation pH and product stability
Edetate disodium	Chelating agent	Supports preservative performance and limits metal-catalyzed degradation
Hydrochloric acid/sodium hydroxide	pH adjustment	Controls comfort, stability and preservative performance
Purified water	Vehicle	Supports aqueous topical ophthalmic delivery

The formulation does not rely on an unusual solubilizer, surfactant, penetration enhancer or proprietary polymer. That profile makes Lastacaft relatively accessible to generic formulation developers, subject to regulatory requirements for pharmaceutical equivalence, bioequivalence and product quality.

Why is benzalkonium chloride commercially important?

Benzalkonium chloride, or BAK, is a widely used ophthalmic preservative. In Lastacaft, it supports multidose packaging and repeated consumer use. Its presence also creates a clear reformulation opportunity.

Repeated exposure to BAK has been associated with ocular-surface irritation and toxicity concerns, particularly in patients with frequent dosing, chronic ocular-surface disease or concurrent use of multiple preserved ophthalmic products.[2] Allergic conjunctivitis is generally episodic, so the clinical impact may be lower than in chronic glaucoma therapy. Even so, a preservative-free or low-preservative Lastacaft alternative could target:

• patients with dry eye or blepharitis;
• contact-lens users;
• pediatric patients requiring repeated seasonal treatment;
• consumers using multiple ophthalmic products;
• ophthalmologists who prefer preservative-free treatment for ocular-surface disease.

The commercial opportunity is strongest if the reformulated product preserves once-daily dosing and can be sold in a convenient multidose container.

What FDA status does Lastacaft have?

Lastacaft was initially approved as a prescription ophthalmic product and later transitioned to over-the-counter status. FDA approved the nonprescription version for temporary relief of itchy eyes associated with allergic conjunctivitis.[3]

Regulatory event	Status
Active ingredient	Alcaftadine
Strength	0.25% ophthalmic solution
Dosage form	Topical ophthalmic solution
Original prescription product	FDA-approved
OTC status	FDA-approved nonprescription product
Dosing	One drop in each affected eye once daily
Primary indication	Temporary relief of itchy eyes due to allergies
Product category	Small-molecule ophthalmic drug
Biosimilar pathway	Not applicable

The OTC switch expanded the addressable market beyond ophthalmology prescribing channels. It also changed the competitive basis from prescription differentiation to consumer recognition, shelf placement, packaging, labeling and retail economics.

When does Lastacaft lose exclusivity?

Lastacaft’s principal active ingredient is a small molecule, so the relevant competitive pathways are generic or authorized-generic entry, not biosimilar substitution. The practical exclusivity analysis depends on several separate rights:

1. alcaftadine compound patents;
2. ophthalmic formulation patents;
3. method-of-use patents;
4. pediatric exclusivity;
5. regulatory exclusivity associated with the NDA or OTC switch;
6. trademark and trade-dress protection.

Public product labeling identifies the formulation and NDA history but does not establish that an active, enforceable patent currently blocks all equivalent alcaftadine ophthalmic products.[1,3] Patent expiration must be assessed by reviewing the FDA Orange Book, patent term adjustments, terminal disclaimers, litigation records and any settlement agreements.

The commercial conclusion is straightforward: Lastacaft should be treated as exposed to formulation competition unless a currently listed and enforceable patent covers the proposed generic product or its labeled use.

How many patents cover Lastacaft?

The number of patents associated with Lastacaft can differ depending on whether the analysis counts:

• patents covering alcaftadine itself;
• patents covering the ophthalmic formulation;
• patents covering manufacturing processes;
• patents covering therapeutic use;
• expired patents;
• Orange Book-listed patents;
• patents assigned to the originator but not listed for the NDA.

A reliable freedom-to-operate analysis therefore cannot use a simple patent count. The relevant commercial question is whether a patent is unexpired, claims the proposed product, is listed against the relevant FDA application, and can support an injunction or damages claim.

For an ANDA applicant, the key event is a Paragraph IV certification against any listed patent. A Paragraph IV notice can trigger patent litigation within 45 days and, if timely filed, a statutory stay of FDA approval of up to 30 months under the Hatch-Waxman framework.[4]

What excipient patents could protect a Lastacaft competitor?

The existing Lastacaft excipient system is composed of standard ophthalmic ingredients. A competitor would have difficulty obtaining strong broad claims over the basic combination of alcaftadine, phosphate buffer, edetate and BAK. More defensible opportunities exist in narrow formulation and delivery claims.

Preservative-free alcaftadine formulations

A preservative-free product could use:

• single-dose unit containers;
• multidose valve bottles;
• one-way dispensing systems;
• antimicrobial container technology;
• oxygen-controlled packaging;
• low-bioburden manufacturing and aseptic filling.

A strong patent position would need to connect the packaging or formulation to measurable product performance, such as preservative-free sterility over a defined in-use period, reduced extractables, improved chemical stability or reduced ocular irritation.

Alternative preservatives

Potential alternatives include polyquaternium-1, stabilized oxychloro complex, sodium perborate systems and other ophthalmic preservative technologies. Each option introduces regulatory and technical issues. A replacement preservative must maintain antimicrobial effectiveness without causing unacceptable irritation or destabilizing alcaftadine.

A patent claim could focus on the concentration range, pH window, buffer capacity, container interaction or stability profile. Broad claims covering a conventional preservative substitution are likely to face validity and obviousness challenges.

Polymer-based comfort and retention systems

Hydroxypropyl methylcellulose, povidone, hyaluronic acid and related polymers could improve retention, lubrication or comfort. These excipients could support a premium formulation designed for patients with allergy-associated dryness or ocular-surface irritation.

The main constraints are viscosity, blinking-related discomfort, drop-size control, bottle performance and the need to demonstrate that the polymer does not alter alcaftadine release or ocular exposure.

Improved bottle and drop-delivery systems

Delivery-device claims may provide more durable differentiation than conventional excipient claims. Commercially relevant features include:

• metered drop size;
• reduced contamination;
• low residual volume;
• one-handed operation;
• child-resistant packaging;
• reduced overflow and spillage;
• compatibility with preservative-free formulations.

For an OTC product, packaging can influence adherence and consumer preference even when the active ingredient and labeled dose remain unchanged.

What formulation strategies create the strongest commercial opportunity?

The best opportunity is a preservative-free, once-daily alcaftadine product with a differentiated dispensing system. A second opportunity is an ocular-surface comfort formulation with a polymeric lubricant. A lower-value opportunity is simply changing the buffer or replacing one conventional preservative with another.

Strategy	Technical value	Patent potential	Commercial attractiveness
BAK-containing generic solution	Low	Low	High for price-based entry
Preservative-free unit-dose product	Moderate	Moderate	Moderate, with higher packaging cost
Preservative-free multidose bottle	High	High if performance is demonstrated	High
Lubricating polymer formulation	Moderate	Moderate	Moderate to high
Alternative preservative	Low to moderate	Low to moderate	Moderate
Extended shelf-life formulation	Moderate	Moderate	Moderate
Improved metered-drop device	High	High	High for premium OTC positioning

A generic developer focused on rapid market entry would likely favor the conventional BAK-preserved solution. A branded lifecycle competitor would have stronger economics in a preservative-free multidose platform, particularly if it could command a premium and obtain favorable retail placement.

What generic entry risks exist for Lastacaft?

Generic entry risk is material because alcaftadine is a small molecule and the labeled formulation uses standard excipients. The main barriers are regulatory rather than scientific.

An ANDA applicant would need to demonstrate pharmaceutical equivalence and establish bioequivalence using FDA-accepted ophthalmic methods. Product development would also need to address:

• sterile manufacturing;
• particulate control;
• preservative effectiveness;
• container-closure integrity;
• drop-size consistency;
• pH and osmolality;
• degradation products;
• extractables and leachables;
• in-use stability.

A conventional generic could compete on price. An alternative formulation may require a new drug application or a more complex regulatory route if it changes the preservative system, delivery device, concentration, dosing regimen or clinical performance.

The OTC status does not eliminate generic competition. It changes labeling, distribution and consumer marketing requirements. An OTC alcaftadine generic would need to comply with applicable nonprescription labeling and packaging requirements while maintaining the necessary product quality standards.

What is the Orange Book status of Lastacaft?

The Orange Book is the primary FDA source for determining whether patents and exclusivity are listed against an approved NDA.[5] Orange Book status can change through patent listing updates, delistings, expiration, litigation outcomes and regulatory amendments.

For Lastacaft, a current diligence review should distinguish:

• the original prescription NDA;
• the OTC product and any related application;
• active ingredient patents;
• formulation patents;
• method-of-use patents;
• pediatric exclusivity;
• any patent litigation or Paragraph IV certifications.

A listed patent does not automatically establish that generic entry is blocked. The patent must cover the proposed product or use, survive validity and enforceability challenges, and remain effective through the expected launch date.

What patent litigation affects Lastacaft?

The principal litigation risk would arise from a Paragraph IV challenge to an Orange Book-listed patent. The likely dispute areas are:

• validity of alcaftadine compound claims;
• obviousness of the ophthalmic formulation;
• written description and enablement;
• infringement by a generic formulation;
• use of the product for allergic conjunctivitis;
• patent listing eligibility;
• the scope of any settlement restriction.

No biosimilar litigation is relevant because Lastacaft is not a biologic. Patent litigation involving a conventional alcaftadine ophthalmic solution would most likely follow the Hatch-Waxman framework rather than the Biologics Price Competition and Innovation Act pathway.

Are there licensing opportunities around Lastacaft excipients?

The most realistic licensing opportunities are outside the alcaftadine molecule itself. They include:

• preservative-free multidose containers;
• ophthalmic valve and metered-dose systems;
• antimicrobial packaging;
• polymeric comfort formulations;
• sterile fill-finish capacity;
• low-extractables container systems;
• OTC ophthalmic brand and retail distribution.

A company holding a delivery-platform patent could license the technology to the originator, a generic manufacturer or a consumer-health company. The value would depend on whether the platform produces measurable benefits, such as a longer in-use period, lower contamination risk, improved dosing accuracy or reduced preservative exposure.

How does Lastacaft compare with competing allergy eye drops?

Lastacaft competes with other antihistamine or dual-action ophthalmic products, including olopatadine, ketotifen and bepotastine products. The principal commercial comparison is once-daily convenience versus price, brand familiarity and preservative profile.

Product category	Typical positioning	Excipient opportunity
Alcaftadine 0.25%	Once-daily allergy relief	Preservative-free and comfort reformulations
Olopatadine ophthalmic products	Broad allergy-eye competition	Device, polymer and preservative differentiation
Ketotifen products	OTC price competition	Low-cost generic and package differentiation
Bepotastine products	Prescription-oriented segment	Prescriber-focused tolerability and formulation claims

Lastacaft’s once-daily dosing supports premium positioning, but standard excipients provide limited technical differentiation. A preservative-free product could improve the competitive narrative without changing the active ingredient.

What revenue exposure does Lastacaft create for excipient suppliers?

Revenue exposure is concentrated in high-volume commodity excipients and specialized packaging.

Commodity suppliers may benefit from recurring demand for:

• benzalkonium chloride;
• phosphate buffers;
• edetate disodium;
• purified water;
• primary plastic containers;
• sterile closures.

Higher-margin opportunities exist in:

• preservative-free multidose dispensing systems;
• ophthalmic polymers;
• low-particulate packaging;
• container-closure integrity testing;
• sterile contract manufacturing;
• OTC-ready packaging and labeling operations.

A BAK-free reformulation would reduce demand for benzalkonium chloride in that product but could increase demand for specialized packaging and sterile fill-finish services. The value shift would move from low-cost formulation inputs toward device, manufacturing and quality-control infrastructure.

What geographic opportunities exist for Lastacaft excipients?

The United States is the most important market for OTC commercialization, retail distribution and Paragraph IV competition. European and other markets may use different brand names, regulatory classifications, preservatives or packaging requirements.

Geographic opportunities include:

• North America: OTC distribution, generic substitution and premium preservative-free products;
• Europe: preservative-reduction strategies driven by ocular-surface tolerability and national reimbursement conditions;
• Japan and South Korea: high standards for ophthalmic product quality and packaging;
• Emerging markets: lower-cost preserved formulations and locally manufactured sterile products.

Patent protection, regulatory exclusivity and product registration must be assessed separately by jurisdiction. A formulation or packaging patent may have commercial value in one market even if the underlying alcaftadine patent has expired globally.

Key Takeaways

• Lastacaft is an alcaftadine 0.25% aqueous ophthalmic solution.
• Its labeled excipients are conventional: BAK, phosphate buffers, edetate disodium, pH adjusters and purified water.
• BAK is the main excipient-driven lifecycle opportunity because a preservative-free product could target ocular-surface tolerability.
• The strongest technical opportunity is a preservative-free multidose bottle with validated sterility and delivery performance.
• A conventional BAK-preserved generic is likely to face fewer formulation barriers than a premium reformulation.
• Biosimilar risk does not apply because alcaftadine is a small molecule.
• Orange Book listings and Paragraph IV certifications determine the principal U.S. patent-entry risks.
• Commercial value is shifting from basic excipients toward dispensing devices, sterile packaging, polymers and OTC distribution.

FAQs

Can a generic manufacturer use the same Lastacaft excipients?

Yes. A generic manufacturer can generally use the same inactive ingredients if the resulting product meets FDA requirements for pharmaceutical equivalence, quality, safety and bioequivalence. The formulation must also comply with any active patent claims.

Is benzalkonium chloride essential to Lastacaft?

No. BAK supports preservation of the multidose product but is not pharmacologically essential to alcaftadine. Removing it would require a different container, sterile strategy or preservative system.

Could a preservative-free Lastacaft formulation receive new patent protection?

Yes, but protection would likely depend on specific claims covering the formulation, packaging, stability, sterility, dispensing performance or measured tolerability benefit. A simple substitution of BAK with another known preservative would face a weaker patent position.

Does OTC approval prevent an ANDA for alcaftadine?

No. OTC status does not by itself eliminate generic competition. The applicant must use the appropriate FDA pathway and satisfy applicable labeling, quality and bioequivalence requirements.

Which Lastacaft excipient has the greatest supplier opportunity?

Specialized preservative-free multidose packaging has the strongest opportunity because it can support product differentiation, premium pricing and formulation claims. Commodity phosphate buffers and purified water are less attractive from a margin and patentability perspective.

References

1. DailyMed. (n.d.). Lastacaft: Alcaftadine ophthalmic solution, 0.25% prescribing information. U.S. National Library of Medicine.
2. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.
3. U.S. Food and Drug Administration. (2022). FDA approves first over-the-counter eye drop to treat itchy eyes due to allergies.
4. U.S. Food and Drug Administration. (2023). Hatch-Waxman Amendments: Questions and answers.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.